Modulation of cerebral malaria by curcumin as an adjunctive therapy

Brazilian Journal of Infectious Diseases

Volumn 17, Issue 5, 2013, Pages 579-591

  Jain, Kunal ^a   Sood, Sumeet ^a   Gowthamarajan, K ^a  

^a JSS COLLEGE OF PHARMACY   (India)

Author keywords

Adjunctive; Cerebral malaria; Cognitive deficit; Curcumin

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ARGININE; ARTEMETHER; ARTESUNATE; CURCUMIN; DEFEROXAMINE; DEXAMETHASONE; GAMMA INTERFERON; HEPARIN; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; PENTOXIFYLLINE; QUINIDINE GLUCONATE; QUININE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; VITAMIN K GROUP;

ADJUVANT THERAPY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIMALARIAL ACTIVITY; APOPTOSIS; BRAIN MALARIA; CELL DAMAGE; CELL DESTRUCTION; CELL MEMBRANE PERMEABILITY; CELLULAR DISTRIBUTION; CLINICAL FEATURE; COGNITIVE DEFECT; CONTINUOUS INFUSION; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROCYTE DEFORMABILITY; HEMAGGLUTINATION; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LOADING DRUG DOSE; MALARIA FALCIPARUM; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARASITE LOAD; PATHOPHYSIOLOGY; PATIENT MONITORING; PLASMODIUM VIVAX MALARIA; PROTEIN EXPRESSION; ROSETTE FORMATION; SHORT SURVEY; THROMBOCYTOPENIA;

EID: 84884724517     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2013.03.004     Document Type: Short Survey

References (115)

1. Joshi M., Pathak S., Sharma S., Patravale V. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of Artemether: Nanoject. Int J Pharm 2008, 364:119-126.
2. World Malaria Report 2010. World Health Organization, Geneva.
3. Kiszewski A., Johns B., Schapira A., et al. Estimated global resources needed to attain international malaria control goals. Bull World Health Organ 2007, 85:623-630.
4. Waknine-Grinberg J.H., Mcquillan J.A., Hunt N., Ginsburg H., Golenser J. Modulation of cerebral malaria by fasudil and other immune-modifying compounds. Exp Parasitol 2012, 125:141-146.
5. WHO Guidelines for the treatment of malaria 2010, Available from:. http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html, second edition.
6. Dondorp A.M. Pathophysiology, clinical presentation and treatment of cerebral malaria. Neurol Asia 2005, 10:67-77.
7. Idro R., Marsh K., John C.C., Newton C.R.J. Cerebral malaria: mechanisms of brain injury and strategies for improved neuro-cognitive outcome. Pediatr Res 2010, 68:267-274.
8. Gay F., Zougbédé S., N'Dilimabaka N., Rebollo A., Mazier D., Moreno A. Cerebral malaria: what is known and what is on research. Rev Neurol (Paris) 2012, 168:239-256.
9. Idro R., Jenkins N.E., Newton C.R. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol 2005, 4:827-840.
10. Beales P.F., Brabin B., Dorman E., et al. Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000, 94:S1-S90.
11. Coltel N., Combes V., Hunt N.H., Grau G.E. Cerebral malaria - a neurovascular pathology with many riddles still to be solved. Curr Neurovasc Res 2004, 1:91-110.
12. Schofield L., Grau G.E. Immunological processes in malaria pathogenesis. Nat Rev Immunol 2005, 5:722-735.
13. Combes V., Coltel N., Faille D., Wassmer S.C., Grau G.E. Cerebral malaria: role of microparticles and platelets in alteration of the blood-brain barrier. Int J Parasitol 2006, 36:541-546.
14. Medana I.M., Turner G.D.H. Human cerebral malaria and blood-brain barrier. Int J Parasitol 2006, 36:555-568.
15. Newton R.J.C., Hien T.T., White N. Cerebral malaria. J Neurol Neurosurg Psychiatry 2000, 69:433-441.
16. Borst P., Bitter W., McCulloch R., Leeuwen F., Rudenko G. Antigenic variation in malaria: mini review. Cell 1995, 82:1-4.
17. David P.H., Hommel M., Miller R.H., Udeinya I.J., Oligino L.D. Parasite sequestration in Plasmodium falciparum malaria: spleen and antibody modulation of cytoadherence of infected erythrocytes. Proc Natl Acad Sci USA 1983, 80:5075-5079.
18. Aikawa M., Kamanura K., Shiraishi S., et al. Membrane knobs of unfixed Plasmodium falciparum infected erythrocytes: new findings as revealed by atomic force microscopy and surface potential spectroscopy. Exp Parasitol 1996, 84:339-343.
19. Silamut K., Phu N.H., Whitty C., et al. A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am J Pathol 1999, 155:395-410.
20. Kyes S.A., Kraemer S.M., Smith J.D. Antigenic variation in Plasmodium falciparum: gene organization and regulation of the var multigene family. Eukaryot Cell 2007, 6:1511-1520.
21. Howard R.J., Barnwell J.W. Roles of surface antigens on malaria-infected red blood cells in evasion of immunity. Contemp Top Immunobiol 1984, 12:127-200.
22. Cooke B., Coppel R., Wahlgren M. Falciparum malaria: sticking up, standing out and out-standing. Parasitol Today 2000, 10:416-420.
23. Turner G.D.H., Morrison H., Jones M., et al. An immunohistochemical study of the pathology of cerebral malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol 1994, 145:1057-1069.
24. Wassmer S.C., Lepolard C., Traore B., Pouvelle B., Gysin J., Grau G.E. Platelets reorient Plasmodium falciparum-infected erythrocyte cytoadhesion to activated endothelial cells. J Infect Dis 2004, 189:180-189.
25. Hviid L., Theander T.G., Elhassan I.M., Jensen J.B. Increased plasma levels of soluble ICAM-1 and ELAM-1 (E-selectin) during acute Plasmodium falciparum malaria. Immunol Lett 1993, 36:51-58.
26. Diamond M.S., Staunton D.E., Fougerolles A.R., et al. ICAM-1 (CD54): a counter receptor for Mac-1 (CD11b/CD18). J Cell Biol 1990, 111:3129-3139.
27. Dustin M.L., Rothlein R., Bhan A.K., Dinarello C.A., Springer T.A. Induction of IL-l and interferon gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 1986, 137:245-254.
28. Collins T., Read M.A., Neish A.S., et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa Band cytokine-inducible enhancers. FASEB J 1995, 9:899-909.
29. Ray B., Lahiri D.K. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol 2009, 9:434-444.
30. Kaul D.K., Liu X.D., Nagel R.L., Shear H.L. Microvascular hemodynamic and in vivo evidence for the role of intercellular adhesion molecule-1 in the sequestration of infected red blood cells in a mouse model of lethal malaria. Am J Trop Med Hyg 1998, 58:240-247.
31. Hughes K.R., Biagini G.A., Craig A.G. Continued cytoadherence of Plasmodium falciparum infected red blood cells after antimalarial treatment. Mol Biochem Parasitol 2010, 169:71-78.
32. Taylor T.E., Fu W.J., Carr R.A., et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med 2004, 10:143-145.
33. Dondorp A.M., Desakorn V., Pongtavornpinyo W., et al. Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med 2005, 2:e204.
34. Marsh K., Marsh V.M., Brown J., Whittle H.C., Greenwood B.M. Plasmodium falciparum: the behavior of clinical isolates in an in vitro model of infected red blood cell sequestration. Exp Parasitol 1988, 65:202-208.
35. Dondorp A.M., Ince C., Charunwatthana P., et al. Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria. J Infect Dis 2008, 197:79-84.
36. Miller L.H., Usami S., Chien S. Alteration in the rheologic properties of Plasmodium knowlesi infected red cell. A possible mechanism for capillary obstruction. J Clin Invest 1971, 50:1451-1455.
37. Dondorp A.M., Angus B.J., Hardeman M.R., et al. Prognostic significance of reduced red cell deformability in severe falciparum malaria. Am J Trop Med Hyg 1997, 57:507-511.
38. Carlson J., Helmby H., Wahlgren M., Hill A.V.S., Brewster D., Greenwood B.M. Human cerebral malaria: association with erythrocyte rosetting and lack of anti-rosetting antibodies. Lancet 1990, 336:1457-1460.
39. Treutiger C.J., Hedlund I., Helmby H., et al. Rosette formation in Plasmodium falciparum isolates and anti-rosette activity of sera from Gambians with cerebral or uncomplicated malaria. Am J Trop Med Hyg 1992, 46:503-510.
40. Barragan A., Spillmann D., Kremsner P.G., Wahlgren M., Carlson J. Plasmodium falciparum: molecular background to strain-specific rosette disruption by glycosaminoglycans and sulfated glycoconjugates. Exp Parasitol 1999, 91:133-143.
41. David P.H., Handunetti S.M., Leech J.H., Gamage P., Mendis K.N. Rosetting: a new cytoadherence property of malaria infected erythrocytes. Am J Trop Med Hyg 1988, 38:289-297.
42. Al-Yaman F., Genton B., Mokela D., et al. Human cerebral malaria: lack of significant association between erythrocyte rosetting and disease severity. Trans R Soc Trop Med Hyg 1995, 89:55-58.
43. Carlson J., Nash G.B., Gabutti V., al-Yaman F., Wahlgren M. Natural protection against severe Plasmodium falciparum malaria due to impaired rosette formation. Blood 1994, 84:3909-3914.
44. Combes V., El-Assaad F., Faille D., Jambou R., Hunt N.H., Grau G.E.R. Microvesiculation and cell interactions at the brain-endothelial interface in cerebral malaria pathogenesis. Prog Neurobiol 2010, 91:140-151.
45. Nebl T., De Veer M.J., Schofield L. Stimulation of innate immune responses by malarial glycosylphosphatidylinositol via pattern recognition receptors. Parasitology 2005, 130:S45-S62.
46. Jacobs P., Radzioch D., Stevenson M.M. A Th1-associated increase in tumor necrosis factor alpha expression in the spleen correlates with resistance to blood-stage malaria in mice. Infect Immun 1996, 64:535-541.
47. Grau G.E., Taylor T.E., Molyneux M.E., et al. Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med 1989, 320:1586-1591.
48. Combes V., Simon A.C., Grau G.E., et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999, 104:93-102.
49. Clark I.A., Rockett K.A., Cowden W.B. Possible central role of nitric oxide in conditions clinically similar to cerebral malaria. Lancet 1992, 340:894-896.
50. Rockett K.A., Awburn M.M., Cowden W.B., Clark I.A. Killing of Plasmodium falciparum in vitro by nitric oxide derivatives. Infect Immun 1991, 59:3280-3283.
51. Gyan B., Troye-Blomberg M., Perlmann P., Björkman A. Human monocytes cultured with and without interferon-gamma inhibit Plasmodium falciparum parasite growth in vitro via secretion of reactive nitrogen intermediates. Parasite Immunol 1994, 16:371-375.
52. Sobolewski P., Gramaglia I., Frangos J., Intaglietta M., van der Heyde H.C. Nitric oxide bioavailability in malaria. Trends Parasitol 2005, 21:415-422.
53. Chotivanich K., Sritabal J., Udomsangpetch R., et al. Platelet induced autoagglutination of Plasmodium falciparum-infected red blood cells and disease severity in Thailand. J Infect Dis 2004, 189:1052-1055.
54. Medana I.M., Day N.P., Hien T.T., et al. Axonal injury in cerebral malaria. Am J Pathol 2002, 160:655-666.
55. Descamps-Latscha B., Lunel-Fabiani F., Kara-Binis A., Druilhe P. Generation of ROS in whole blood from patients with acute falciparum malaria. Parasite Immunol 1987, 9:275-279.
56. Becker K., Tilley L., Vennerstrom J.L., Roberts D., Rogersone S., Ginsburg H. Oxidative stress in malaria parasite-infected erythrocytes: host-parasite interactions. Int J Parasitol 2004, 34:163-189.
57. Tilley L., Loria P., Foley M. Chloroquine and other quinoline antimalarials. Antimalarial chemotherapy 2001, Humana Press, Totowa. R.P.J. Totowa (Ed.).
58. Olliaro P.L., Haynes R.K., Meunier B., Yuthavong Y. Possible modes of action of the artemisinin-type compounds. Trends Parasitol 2001, 17:122-126.
59. Robert A., Dechy-Cabaret O., Cazelles J., Meunier B. From mechanistic studies on artemisinin derivatives to new modular antimalarial drugs. Acc Chem Res 2002, 35:167-174.
60. Hawkins B.T., Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005, 57:173-185.
61. Adams S., Brown H., Turner G. Breaking down the blood-brain barrier: signaling a path to cerebral malaria. Trends Parasitol 2002, 18:360-366.
62. Medana I.M., Chaudhri G., Chan-Ling T., Hunt N.H. Central nervous system in cerebral malaria: 'Innocent bystander' or active participant in the induction of immunopathology. Immunol Cell Biol 2001, 79:101-120.
63. Esamai F., Mining S., Forsberg P., Lewis D.H. A comparison of brain, core and skin temperature in children with complicated and uncomplicated malaria. J Trop Pediatr 2001, 47:170-175.
64. Pino P., Vouldoukis I., Kolb J.P., et al. Plasmodium falciparum-infected erythrocyte adhesion induces caspase activation and apoptosis in human endothelial cells. J Infect Dis 2003, 187:1283-1290.
65. Claser C., Malleret B., Gun S.Y., et al. CD8+ T cells and IFN-gamma mediate the time-dependent accumulation of infected red blood cells in deep organs during experimental cerebral malaria. PLoS ONE 2011, 6:e18720.
66. Maegraith B., Migasena A. The movement of fluorescent isothiocyanate (F.I.T.C.) labelled human albumin from blood into brain tissue examined by fluorescent technique in normal and Plasmodium knowlesi infected Macaca mulatta. Med J Malaya 1968, 22:251.
67. Newton C.R., Crawley J., Sowumni A., et al. Intracranial hypertension in Africans with cerebral malaria. Arch Dis Child 1997, 76:219-226.
68. The South east Asian quinine artesunate malaria trial (seaquamat) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005, 366:717-725.
69. Brewster D.R., Kwiatkowski D., White N.J. Neurological sequelae of cerebral malaria in children. Lancet 1990, 336:1039-1043.
70. Holding P.A., Stevenson J., Peshu N., Marsh K. Cognitive sequelae of severe malaria with impaired consciousness. Trans R Soc Trop Med Hyg 1999, 93:529-534.
71. Dai M., Reznik S.E., Spray D.C., et al. Persistent motor and cognitive deficits after successful antimalarial treatment in murine cerebral malaria. Microbes Infect 2011, 12:1198-1207.
72. Kihara M., Carter J.A., Holding P.A., et al. Impaired everyday associated with encephalopathy of severe malaria: the role of seizures and hippocampal damage. Malar J 2009, 8:273.
73. Newton C.R., Krishna S. Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment. Pharmacol Ther 1998, 79:1-53.
74. White N.J. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 2011, 10:297.
75. Price R.N., Tjitra E., Guerra C.A., Yeung S., White N.J., Anstey N.M. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007, 77:79-87.
76. Pereira E.A., Ishikawa E.A.Y., Fontes C.J.F. Adherence to Plasmodium vivax malaria treatment in the Brazilian Amazon region. Malar J 2011, 10:355.
77. Costa F.T.M., Lopes S.C.P., Albrecht L., et al. On the pathogenesis of Plasmodium vivax malaria: perspectives from the Brazilian field. Int J Parasitol 2012, 42:1099-1105.
78. Thapa R., Patra V., Kundu R. Plasmodium vivax cerebral malaria. Indian Pediatr 2007, 44:433-434.
79. World Health Organization. Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000, 94:1-90.
80. Anstey N.M., Handojo T., Pain M.C. Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and post-treatment alveolar capillary inflammation. J Infect Dis 2007, 195:589-596.
81. Price L., Planche T., Rayner C., Krishna S. Acute respiratory distress syndrome in Plasmodium vivax malaria: case report and review of the literature. Trans R Soc Trop Med Hyg 2007, 101:655-659.
82. Anstey N.M., Russell B., Yeo T.W., Price R.N. The pathophysiology of vivax malaria. Trends Parasitol 2009, 25:220-227.
83. Andrade B.B., Reis-Filho A., Souza-Neto S.M., et al. Severe Plasmodium vivax malaria exhibits marked inflammatory imbalance. Malar J 2010, 9:13.
84. Campose F.M., Franklin B.S., Teixeira-Carvalho A., et al. Augmented plasma microparticles during acute Plasmodium vivax infection. Malar J 2010, 9:327.
85. Carvalho B.O., Lopes S.C., Nogueira P.A., et al. On the cytoadhesion of Plasmodium vivax infected erythrocytes. J Infect Dis 2010, 202:638-647.
86. Rogerson S.J., Carter R. Severe vivax malaria: newly recognised or rediscovered?. PLoS Med 2008, 5:e136.
87. Poespoprodjo J.R., Fobia W., Kenangalem E., et al. Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis 2009, 48:1704-1712.
88. Bienvenu A.L., Ferrandiz J., Kaiser K., Latour C., Picot S. Artesunate-erythropoietin combination for murine cerebral malaria outcome. Acta Trop 2008, 106:104-108.
89. Hunt N.H., Grau G.E. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. Trends Immunol 2003, 249:491-499.
90. Reis P.A., Comim C.M., Hermani F. Cognitive dysfunction is sustained after rescue therapy in experimental cerebral malaria, and is reduced by additive antioxidant therapy. PLoS Pathog 2010, 6:e1000963.
91. Dondorp A.M., Omodeo-Sale F., Chotivanich K., Taramelli D., White N.J. Oxidative stress and rheology in severe malaria. Redox Rep 2003, 8:292-294.
92. White N.J., Turner G.D., Medana I.M., Dondorp A.M., Day N.P. The murine cerebral malaria phenomenon. Trends Parasitol 2010, 26:11-15.
93. Jain K., Gowthamarajan K., Sood S., Elango K., Suresh B. Olfactory drug delivery of artemether-curcumin combination for management of cerebral malaria. Malaria J 2012, 11(Suppl. 1):P51.
94. Kunnumakkara A.B., Anand P., Aggarwal B.B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signalling proteins. Cancer Lett 2008, 269:199-225.
95. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S. Phase I clinical trial of curcumin, a chemopreventive agent, in the patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21:2895-2900.
96. Reddy R.C., Vatsala P.G., Keshamouni V.G., Padmanaban G., Rangarajan P.N. Curcumin for malaria therapy. Biochem Biophys Res Commun 2005, 326:472-474.
97. Nandakumar D.N., Nagaraj V.N., Vathsala P.K., Rangarajan P., Padamanaban G. Curcumin-artemisinin combination therapy for malaria. Antimicrob Agents Chemother 2006, 50:1859-1860.
98. Vathsala P.G., Dende C., Nagaraj V.A., et al. Curcumin-arteether combination therapy of Plasmodium berghei-infected mice prevents recrudescence through immunomodulation. PLoS ONE 2012, 7:1-10.
99. Cui L., Miao J., Cui L. Cytotoxic effect of curcumin on malarial parasite Plasmodium falciparum: inhibition of histone acetylation and generation of reactive oxygen species. Antimicrob Agents Chemother 2007, 51:488-494.
100. Mimche P.N., Taramelli D., Vivas L. The plant-based curcumin as a potential candidate for the development of an adjunctive therapy for cerebral malaria. Malar J 2011, 10(Suppl. 1):S10.
101. Golenser J., McQuillan J., Hee L., Mitchell A.J., Hunt N.H. Conventional and experimental treatment of cerebral malaria. Int J Parasitol 2006, 36:583-593.
102. Serghides L., Kain K.C. Peroxisome proliferator-activated receptor gamma-retinoid X receptor agonists increase CD36-dependent phagocytosis of Plasmodium falciparum-parasitized erythrocytes and decrease malaria induced TNF-alpha secretion by monocytes/macrophages. J Immunol 2001, 166:6742-6748.
103. Rushworth S.A., Ogborne R.M., Charalambos C.A., O'Connell M.A. Role of protein kinase C [delta] in curcumin-induced antioxidant response element-mediated gene expression in human monocytes. Biochem Biophys Res Commun 2006, 341:1007-1016.
104. Innamorato N.G., Rojo A.I., Garcia-Yague A.J., Yamamoto M., de Ceballos M.L., Cuadrado A. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 2008, 181:680-689.
105. Zhang L., Gu Z.L., Qin Z.H., Liang Z.Q. Effect of curcumin on the adhesion of platelets to brain microvascular endothelial cells in vitro. Acta Pharmacol Sin 2008, 29:800-807.
106. 2+ pumps by curcumin: curcumin putatively stabilizes the interaction between the nucleotide binding and phosphorylation domains in the absence of ATP. Eur J Biochem 2001, 268:6318-6327.
107. Eckstein-Ludwig U., Webb R.J., Van Goethem I.D., et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003, 424:957-961.
108. Pan M.H., Lin-Shiau S.Y., Lin J.K. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem Pharmacol 2000, 60:1665-1676.
109. Morse D., Choi A.M. Heme oxygenase-1: the emerging molecule has arrived. Am J Respir Cell Mol Biol 2002, 27:8-16.
110. Motterlini R., Foresti R., Bassi R., Green C.J. Curcumin, an antioxidant and anti inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med 2000, 28:1303-1312.
111. Anand S.S., Babu P.P. c-Jun N terminal kinases (JNK) are activated in the brain during the pathology of experimental cerebral malaria. Neurosci Lett 2011, 488:118-122.
112. Aditya N.P., Chimote G., Gunalan K., Banerjee R., Patankar S., Madhusudhan B. Curcuminoids-loaded liposomes in combination with arteether protects against Plasmodium berghei infection in mice. Exp Parasitol 2012, 131:292-299.
113. Akhtar F., Rizwi M.M.A., Kar S.K. Oral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelii infected mice. Biotechnol Adv 2011, 30:310-320.
114. Nayak A.P., Tiyaboonchai W., Patankar S., Madhusudhan B., Souto E.B. Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment. Colloids Surf B 2010, 81:263-273.
115. Martinelli A., Rodrigues L.A., Cravo P. Plasmodium chabaudi: efficacy of artemisinin+curcumin combination treatment on a clone selected for artemisinin resistance in mice. Exp Parasitol 2008, 119:304-307.